Kornimate/medical-research-clean huggingface dataset:
novel dietary interventions for treating insulin resistance

Conditions: Insulin Resistance; Obesity; Metabolic Syndrome

Summary: clinical and rodent studies have demonstrated the impact of specific dietary factors in modulating inflammation-related diseases including insulin resistance, type 2 diabetes, and cardiovascular disease. such dietary factors include polyunsaturated fats, polyphenols, and glycemic index. the investigators know from previous studies in the literature that reducing the glycemic index and increasing the omega-3 fat and polyphenol content of the diet results in improved metabolic indices and reduced inflammation. these improvements can be observed even within the context of persistent obesity. the investigators will implement a reduced-calorie, multi-pronged dietary approach for improving insulin sensitivity and reducing inflammation in obese subjects with the metabolic syndrome. the active diet will include reduced glycemic index foods together with omega-3 fats and polyphenol supplements. the primary hypothesis is that the dietary combination of reduced glycemic index foods, omega-3 fats and polyphenols will work to reduce insulin resistance and inflammation more efficiently than a placebo-controlled, calorie- and macronutrient-matched diet in obese subjects with the metabolic syndrome.


Eligibility criteria:
inclusion criteria: * body mass index (bmi): 30.0-40.9 kg/m\^2 * metabolic syndrome exclusion criteria: * diabetes * inflammatory diseases * eating disorders * pregnancy * known kidney, coronary, gastrointestinal or peripheral artery disease * smoking * recent fish oil (\>500mg eicosapentaenoic acid (epa) + docosahexaenoic acid (dha)/day) or polyphenol supplement use * recent weight change * strenuous exercise * fish/food allergies * current diabetic, lipid-lowering (fibrates, statins), anti-inflammatory, immune-suppressant, and/or anti-inflammatory hypertension medication use

Keywords: inflammation monocytes
kinematic comparison of vanguard xp and vanguard cr total knee arthroplasties

Conditions: Osteoarthritis

Summary: primary: the primary objective of this pilot study is to compare the intraarticular kinematics by fluoroscopy of vanguard xp to that of vanguard cr. secondary: the secondary objective of this pilot study is to compare the standing balance by force plate of patients with the vanguard xp prosthesis to those who have vanguard cr prosthesis. furthermore, we wish to assess isometric quadriceps muscle strength in both groups.


Eligibility criteria:
inclusion criteria: * participant in the xp vs. cr study (inherited traits from study inclusion) * overall healthy. have attended standard physiotherapy after unilateral total knee replacement * are able to perform the tasks * excellent clinical scores (oxford knee score above 39 at 1 year follow up) exclusion criteria: * knee pain above 20 on a 0-100 visual analogue scale * any clinical relevant pain from adjacent joints * active knee flexion below 100 * signs of implant migration, loosening, and implant mal-alignment
real-world study on adjuvant therapy combined with shenlingcao oral liquid in patients for stage ii and iiia non-small cell lung cancer after radical resection

Conditions: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant

Summary: this study will establish a multi-center, prospective registration database. the included population are stage ii and iiia nsclc patients undergoing r0 resection and will be scheduled for adjuvant chemotherapy. before the first adjuvant chemotherapy, under the recommendation of a doctor, patients will voluntarily choose to use (exposed group) or not to use (control group) shenlingcao oral liquid, which donated by jiangzhong group for 30 bottles. the research centers need to be consecutively enrolled patients according to the allocation of the number of cases according to the ratio of 3: 1 in exposure group and control group. the exposed and control groups will be followed up to 36 months (non-allelic follow-up). information from patients will be prospectively collected, including baseline, chemoradiation, use of shenlingcao oral liquid and the other complementary drugs, and various outcome measures (the questionnaire of eortc qlq, death, tumor recurrence, tumor metastasis, and chemotherapy-induced side effects of the blood system, etc.). follow-up points included: baseline (before giving chemotherapy), 2-3 days after each chemotherapy cycle, and 6,12,18,24,30,36 months after enrollment.


Eligibility criteria:
inclusion criteria: * age 18 or older; * pathological diagnosis of patients with stage ii, iii a primary nsclc; * r0 resection has been accepted; * received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery; * informed consent has been signed. exclusion criteria: * incorporation of other malignant tumors (such as leukemia, liver cancer, etc.)； * patients with unclear pathological types； * patients with unclear pathological staging； * preserved shenlingcao oral liquid before r0 resection surgery； * received immunotherapy or targeted therapy before r0 resection surgery； * radiotherapy and chemotherapy before r0 resection surgery.
genetic testing of cyp2c19 in prognostic evaluation of long-term major adverse cardiac and vascular events

Conditions: Atherosclerotic Vascular Disease; Coronary Arterial Disease (CAD); Atherosclerosis of Coronary Artery; Atherosclerosis of Arteries of the Extremities, Unspecified; Heart Diseases; Stroke; Venous Thromboembolic Disease

Summary: several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (mace), including acute coronary syndrome, depends on the polymorphism of the cyp2c19 gene. however, studies with large sample sizes and long-term follow-up are missing. moreover, the impact of this polymorphism on the risk of major adverse limb events (male), particularly in patients with peripheral artery disease of the lower limb, is unexplored. additionally, the impact of cyp2c19 gene polymorphism on clopidogrel effectiveness in preventing recurrent stroke in diverse populations is unknown since most of the data are from asian ancestry populations. we hypothesize that patients with cyp2c19 gene loss of function alleles are at high risk of mace and male compared to those without loss of function alleles at long-term follow-up. we propose to assess mace and male in a large cohort of patients with available cyp2c19 genotypes treated at the university of florida health to evaluate the impact of cyp2c19 gene polymorphisms on the risk of new or recurrent events at long-term follow-up. our specific aims are aim 1) to determine the impact of cyp2c19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of mace (a composite of all-cause death, non-fatal mi, and non-fatal stroke) at long-term follow-up; aim 2) to evaluate the impact of cyp2c19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of male (a composite of limb amputations, chronic threatening limb ischemia, acute limb ischemia, and limb revascularization) at long-term follow-up; and aim 3) to evaluate the impact of cyp2c19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of cerebrovascular events (cve, a composite of any stroke and transient ischemic attack) at long-term follow-up.


Eligibility criteria:
inclusion criteria: * all patients aged ≥18 years with available cyp2c19 genotyping results obtained within the predefined period. exclusion criteria: * absence of cyp2c19 genotyping results obtained within the predefined period.

Keywords: cardiovascular disease atherosclerotic vascular disease coronary artery disease stroke
assessment of maxillary sinus septum and its prevalence in a sample of egyptian population (cbct)

Conditions: Maxillary Sinus

Summary: a cross-sectional study to estimate the prevalence of maxillary sinus septum and assessment of it in a sample of egyptian population using cone beam computed tomography through retrospective data analysis

setting and location: 1. the data collection will be obtained from the data base available at the department of oral and maxillofacial radiology, faculty of dentistry, cairo university, cairo, egypt. 2. cbct images will be obtained from egyptian patients who had cbct examination as part of their dental examination, diagnosis or treatment planning. participants: a total sample of 111examined sinus belonging to egyptian individuals will be included. variables: 1. prevalence of maxillary sinus septa. 2. location of maxillary sinus septa. 3. orientation of maxillary sinus septa in dentulous \& edentulous individual. data sources / measurements: * retrospective data collection will be performed after the cbct images are pooled from the computer database. * all the cbct examinations will be scanned using cbct machine (planmeca promax 3d mid). * cbct scans using different fields of view, and different voxel resolutions . * cbct images will be interpreted by two oral radiologists independently; blinded from demographic data of the patients and from the results of each other. * each one will evaluate the images separately twice with a period of two weeks between the two reading sessions. * then inter-observational and intra-observational variability between the observers will be evaluated. bias: no source of bias. study size: the results showed that a total sample size of 111examined sinus will be adequate to detect sinus septum prevalence of 24.6% with an 8% margin of error, a significance level of 5% and a 95% confidence interval. quantitative variables: the number of cbct scans of egyptian individuals with maxillary sinus septa will be counted to estimate the variations in the egyptian population. statistical methods: data will be analysed using ibm spss advanced statistics (statistical package for social sciences), version 21 (spss inc., chicago, il). numerical data will be described as mean and standard deviation or median and range. categorical data will be described as numbers and percentages.

Eligibility criteria:
inclusion criteria: * • cbct scans of partially, fully edentulous and dentulous population. exclusion criteria: * • cbct scans that not displaying all the extension of the lower one third of the maxillary sinus. * presence of large pathological lesions involving the maxillary sinus or affecting the confines of the sinus floor. * images exhibiting changes in the morphology of sinus walls due to trauma. * presence of technical artifacts that make difficult the maxillary sinus evaluation.

Keywords: maxillary sinus sinus septa sinus septum cbct
preoperative imrt with concurrent anlotinib for localised extremity or trunk sarcoma

Conditions: Sarcoma,Soft Tissue; Extremity; Trunk; Anlotinib; Intensity-modulated Radiotherapy; Major Wound Complications

Summary: to investigate the safety and efficacy of preoperative imrt and concurrent anlotinib hydrochloride for primary truncal or extremity soft tissue sarcoma; to investigate the quality of life and extremity function post-combination treatment; to study the mechanism of radio-sensitizing effects of anlotinib hydrochloride for primary truncal or extremity soft tissue sarcoma; to assess the relationship between the mri imaging, pathological findings and local control.


Eligibility criteria:
inclusion criteria: * age older than 18-yo * histology proven soft tissue sarcoma of truncal or extremity, deemed appropriate for preoperative radiotherapy and conservative surgery by multidisciplinary discussion. * ecog 0-3 * histology reviewed by reference pathologist * lesion can be assessed * can tolerate radiotherapy and anlotinib * agree contraception. * informed consent: all patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed exclusion criteria: * no gross tumor post-resection in other center. * contraindications to anlotinib, including allergic to anlotinb, active bleeding, ulcer, enteric perforation, enteric obstruction, uncontrolled hypertension, grade 3 to 4 cardiac insufficiency (per nyha criteria), and severe hepatic or renal insufficiency (grade 4), etc. * dermatofibrosarcoma protuberans(dfsp), desmoids, etc. * benign histology * secondary cancer within 5 years (except cervical carcinoma in situ or early-stage skin basal cell carcinoma) * sts can be cured by extensive operation alone. * previous irradiation to the same area * radiological evidence of distant metastases * other contraindications, can't tolerate operation or other treatment needed in this study. * neoadjuvant chemotherapy given or planned.
connective tissue motion measure 2

Conditions: Low Back Pain; Musculoskeletal Pain

Summary: this study aims to compare the connective tissue motion measure (ctmm) in low back pain and no-low back pain subjects, evaluate the reliability of the ctmm, and examine the correlation of ctmm with low back pain symptoms, disability, and functional measures. the investigators hypothesize that ctmm will be reduced, on average, in low back pain subjects, that ctmm will be reliable with an intra-class correlation greater than 0.8, and ctmm will negatively correlate with low back pain symptoms, disability and functional measures.


Eligibility criteria:
inclusion criteria for all subjects: * able to stand and walk without assistance * able to read and understand english * able to understand and sign a consent form inclusion criteria for low back pain subjects: * history of recurrent or chronic low back pain inclusion criteria for no-low back pain subjects: * no history of low back pain or other chronic pain that has limited activities of daily living or work * numerical chronic pain index of less than 0.5 exclusion criteria for all subjects: * previous severe back or lower extremity injury or surgery * major structural spinal deformity (scoliosis, kyphosis, stenosis) * ankylosing spondylitis or rheumatoid arthritis * neurological deficit (weakness or sensory loss, decreased deep tendon reflexes suggesting nerve root compression, but not subjective symptoms of nerve root irritation (sciatica)) * radicular pain * neurological or major psychiatric disorder * bleeding disorders * corticosteroid or anticoagulant medication * substance abuse * pregnancy * active worker's compensation or disability case * in litigation for a low back pain problem * acute systemic infection
impact of the covid-19 pandemic on the surgical activity of bellvitge university hospital

Conditions: Covid19; Surgery--Complications; Nosocomial Infection

Summary: covid-19 has been a challenge for hospitals; there was an obvious need to reconvert many spaces in specific areas to attend this pathology, without forgetting the attention to other pathologies and surgery. the objective of the investigators is to evaluate the impact of this pandemic in the patients who underwent surgery in bellvitge university hospital, analyzing 2 periods of time: the months before the covid-19 peak and the covid-19 peak months.

a total of 2.530 procedures have been evaluated in this retrospective observational study. two groups have been generated (pre-pandemic period and pandemic period), classified into scheduled and emergency surgery. the investigators determined age, type of surgery and specialty, hospital stay, destination at discharge including mortality and severity according to diagnostic related to group (drg) scale. the investigators have also determined the number of confirmed covid-19 infections in patients who underwent surgery during these 2 periods and evaluated if the infection was due to a nosocomial infection (confirmation of the covid-19 during the hospitalization period). comparisons were made between subgroups: scheduled surgery performed during the 2 periods and emergency surgery performed during the 2 periods.

Eligibility criteria:
inclusion criteria: * all surgical patients operated, both elective scheduled and emergent cases exclusion criteria: * minor-intermediate surgery that involves discharge from the hospital on the same day of the surgery from the pre-pandemic period. * procedures related to medical treatment or complications of covid-19 patients, such as chest tubes, extracorporeal oxygenation or tracheostomy. * those scheduled elective surgery patients in the covid period that resulted rt-pcr positive, surgery was posponed, were not considered eligible for the analysis.

Keywords: covid19 hospital stay mortality surgery complications scheduled surgery emergency surgery
body awareness therapy and biomarkers in fibromyalgia

Conditions: Fibromyalgia

Summary: a randomized trial of basic body awareness therapy (bbat) is applied in fibromyalgia patients as compared with a control intervention consisting of stretching. sessions of bbat lasted 90 min each and took place twice a week form 12 weeks. the primary end point is a change in the biomarkers and neurotransmitters and the fibromyalgia impact questionnaire and the secondary end points include visual analog scale, state trait anxiety inventory, beck depression inventory. all assessments will be repeated at post treatment, 12 and 24 weeks and 1 year follow-up.

this work is a clinical trial of randomized and controlled groups. the hypothesis of study is that bbat applied in patients with fibromyalgia improves, more than stretching exercises, the pain, normalization biomarkers, improve in psychological state and quality life. the study population will be selected followed the inclusion criteria of fibromyalgia, and will be selected in consorci sociosanitari of anoia, the patients will be divided in 2 groups, control and treatment group. the groups will be examined at the begin, at 2 weeks, at the end of treatment and 3, 6 and 12 months follow-up. the dependence measurements will be biomarkers serotonin, dopamine and cortisol, also visual analog scale, state trait anxiety inventory (stai a/r), beck depression inventory (bdi-ii) and fibromyalgia impact questionnaire (fiq). the independence measurements will be demographic items: sex, age, country, level of studies, social status...

Eligibility criteria:
inclusion criteria: * whose diagnosed of fibromyalgia almost 6 months before * whose could be in different position such as lying, sitting, and stand-up exclusion criteria: * whose are diagnosed of disease that it worse the pain * pregnancy * whose are diagnosed of other disease such as rheumatology, neurology, cardiac problems o another internal medical condition,malignant disease or acute infections

Keywords: body awareness therapy physical therapy serotonin cortisol
a phase 2, placebo-controlled study to evaluate the efficacy and safety of pf-00489791 in patients with type 2 diabetes and overt nephropathy

Conditions: Diabetic Nephropathies

Summary: pf-00489791 is an inhibitor of phosphodiesterase type 5. our hypothesis is that pf-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.


Eligibility criteria:
inclusion criteria: * male or female subjects greater than or equal to 18 years. female subjects must be of non-child bearing potential. * clinical diagnosis of type 2 diabetes together with stages 3a, 3b or 4 ckd, based on an egfr of 25-59 ml/min/1.73m2. * evidence of persistent, overt albuminuria; defined as a uacr greater than or equal to 300 mg/g (greater than or equal to 33.9 mg/mmol) for greater than 3 months. exclusion criteria: * subjects with ckd resulting from type 1 diabetes or non-diabetic ckd. * subjects with poorly controlled diabetes mellitus, defined as hba1c \>9%. * subjects on combination ace inhibitor/arb therapy.

Keywords: diabetic nephropathy chronic kidney disease pf-00489791 phosphodiesterase pde5
a 6-week safety & efficacy study of combination intraocular pressure-lowering therapy in patients with open-angle glaucoma or ocular hypertension

Conditions: Glaucoma, Open-angle; Ocular Hypertension

Summary: to compare the intraocular pressure(iop)-lowering efficacy of morning or evening instillations of a combination iop-lowering therapy in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
adult patients of any race and either sex with open angle glaucoma or ocular hypertension.

Keywords: glaucoma poag oag oht
bleeding patterns in sequential and continuous progesterone supplementation in adolescents with turner syndrome

Conditions: Turner Syndrome; Primary Ovarian Insufficiency (Poi)

Summary: this is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst turner syndrome (ts) patients with primary ovarian insufficiency (poi) prescribed hormone replacement therapy (hrt).


Eligibility criteria:
inclusion criteria: * diagnosis of turner syndrome and primary ovarian insufficiency. * prescribed adult dosing\* of transdermal or oral estradiol for estrogen replacement therapy. \*adult dosing of will be defined per published clinical practice guidelines from the 2023 international turner syndrome meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol). * have achieved menarche. exclusion criteria: * disclosure of sexual activity and desire for contraception. * having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place. * having received depot medroxyprogesterone within one year prior to study recruitment. * non-english or non-spanish speaking.

Keywords: turner syndrome primary ovarian insufficiency hormone replacement therapy
swedish microinvasive glaucoma surgery study (smigs)

Conditions: Open Angle Glaucoma; Cataract; Kahook Dual Blade Glide; Istent Inject W; MIGS; Goniotomy

Summary: the purpose of the study is to investigate the efficacy of cataract surgery as stand-alone compared to cataract surgery in combination with kahook dual blade glide goniotomy (kdb) or istent inject w trabecular microbypass stent (istent) in eyes with open-angle glaucoma.

glaucoma patients with significant cataract are being informed about the study and potential risks, all participants giving written informed consent and meeting the criteria will become eligibility for study entry. participants meeting the eligible requirements will be randomized to cataract surgery as stand-alone (40 patients) or cataract surgery combined with kahook dual blade glide (40 patients) or istent inject w (40 patients).

Eligibility criteria:
inclusion criteria: * only one eye per participant * clinically significant cataract * glaucoma or intraocular hypertension treated with one to four medications and no need for filtering glaucoma surgery at the time of study enrollment. * open chamber angle with schaffer grading three to four in at least two quadrants exclusion criteria: * previous glaucoma surgery, including cyclodestructive procedures. * selective laser trabeculoplasty (slt) within 90 days prior to planned surgery. * exudative age-related macular degeneration, proliferative diabetic retinopathy, clinically significant corneal dystrophy, other eye disease that affect intraocular eye pressure or visual field. * unable to participate and make written consent due to another medical condition.